We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Updated Basal Calcitonin Cutoffs Predict Extent of Lymph Node Metastasis in Medullary Thyroid Cancer — Practical Thresholds for Surgery Planning

MedXY Editorial Team•Nov 23, 2025•news
medullary thyroid carcinoma

Highlights

– New preoperative basal calcitonin thresholds from a large multicenter cohort (N=509) correlate with the anatomical extent of lymph node metastasis in medullary thyroid carcinoma (MTC).

– Proposed cutoffs: 241.9 pg/mL for central compartment involvement; 693.9 pg/mL for ipsilateral lateral neck; 2378.5 pg/mL for bilateral/contralateral lateral neck; 2787.1 pg/mL for upper mediastinal metastasis.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Compartment-Specific Nodal Recurrence in Medullary Thyroid Cancer: Evaluating the Role of Contralateral Prophylactic Central Neck DissectionThis multicenter study assesses recurrence patterns in medullary thyroid cancer, finding ipsilateral neck sites are the most common recurrence locations, with limited evidence supporting routine contralateral prophylactic central neck disseSep 7, 2026Revisiting Level VII Lymph Node Metastasis in Medullary Thyroid Cancer: A Crucial Prognostic SubgroupLevel VII lymph node metastasis in medullary thyroid cancer signifies a highly aggressive phenotype with the poorest prognosis. Reclassifying level VII nodes as N1b improves prognostic accuracy and could refine staging and treatment strategJun 25, 2026A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on SelpercatinibThis case report details successful management of RET-altered medullary thyroid carcinoma using tarlatamab after selpercatinib progression, highlighting modified dosing to mitigate toxicities and achieve complete response.Jun 11, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib
A 64-year-old man with RET-altered medullary thyroid carcinoma who progressed on selpercatinib achieved complete response after modified dosing of tarlatamab with manageable CRS/ICANS.
Jun 10, 2026
Calcitonin Doubling Rate Sharpens Postoperative Recurrence Risk Stratification in Medullary Thyroid Carcinoma With Biochemical Persistent DiseaseIn medullary thyroid carcinoma with biochemical persistent disease after surgery, an early postoperative calcitonin doubling rate of at least 0.3/year strongly identified patients at higher recurrence risk and may help tailor surveillance iMay 4, 2026
Patient-Derived Medullary Thyroid Cancer Models Capture Tumor Plasticity and Drug Resistance Beyond GenomicsPatient-derived medullary thyroid cancer models preserved tumor heterogeneity, microenvironmental stem-like features, and variable tyrosine kinase inhibitor response, supporting more personalized preclinical testing.Apr 1, 2026